Cerebral Assessment Systems (CAS)
Dr. Charles J. Duffy, M.D., Ph.D., is Cerebral Assessment Systems’ founder, and the inventor of the Cognivue® cerebral assessment solution.
Cognivue is based on years of neurophysiology and psychophysical research focusing on early detection of late-life cognitive decline (LLCD) and dementia.
Dr. Duffy’s interest in LLCD and detection of Mild Cognitive Impairment (MCI) started as an undergraduate at Harvard University’s Harvard College, where he conducted the first hippocampal slice research in the country. Little did he know at the time that LLCD would not only later affect his family, but also become a global epidemic—with more than $600 billion spent annually on dementia care.
For more on Dr. Duffy, please refer to Q&A with the CEO of Cerebral Assessment Systems
Research Behind the Technology
The research most relevant to CAS technology began at the National Eye Institute at the National Institutes of Health, and extended for more than 23 years at the University of Rochester Medical Center, where Dr. Duffy is also a Professor of Neurology. The goal of the research was to better understand the distinct neural mechanisms of impairment in aging, including dementia and Alzheimer’s disease.
At CAS, Dr. Duffy conducted a series of exhaustive Food and Drug Administration (FDA)-supervised studies. The final, pivotal study in this series led to FDA clearance of Cognivue.
What is Cognivue?
The Cognivue cognitive assessment system is the first-of-its-kind, computer-based solution to assess, measure, and monitor brain health to detect early signs of dementia in patients over the age of 55.
The Value of Cognivue with Dr. Duffy
Dr. Duffy discusses both the human and economic toll of the worldwide epidemic of dementia—as well as the Cognivue cognitive assessment system solution for automated measuring and monitoring of brain health and detecting the early signs of dementia.
“Early and accurate diagnosis leads to better disease management, patient outcomes and improved quality of life. It also can lower state and patient costs through an orderly plan for care, rather than one filled with crisis, frequent hospital visits and unanticipated expenses. Alzheimer’s can be a cruel disease. While there is yet no cure, early diagnosis and disease management can help ease the burden on patients, their families and the state budget. We urge our lawmakers to support this reasonable budget allocation.”
Bruce L. Miller, professor of neurology at the University of California, San Francisco, and director of the UCSF dementia center.
Bringing Cognitive Care to Primary Care™
The single, unifying mission of CAS is to bring cognitive care to primary care—and in so doing, make routine assessment and monitoring of brain health and detection of the early signs of dementia more accessible, available, and accurate for physicians and patients worldwide.
No referrals are necessary. Cognivue is a rapid, office-based solution for routine brain health monitoring and detection of dementia when indicated at the patient’s or caregiver’s request.
- 10 tests in 10 minutes
- Cost is reimbursable
For Patients and Family
Cognivue enables brain health testing, which can detect early signs of dementia, for patients in all healthcare settings—working with their personal physician, who knows them best.
- Accessible testing across time and location
- Immediate results
- Single, quantitative brain health score
For Integrated Delivery Networks (IDNs) and Payors
Cognivue enables early dementia detection, which promotes more effective treatment and better outcomes, such as:
- Treating reversible dementia
- Managing co-morbidities
- Avoiding complications, polypharmacy, and procedures
For the Industry
Cognivue provides rapid, standardized CRO brain health testing of new molecules.
- CogniWheel™ global patient interface
- Cloud-based results, storage, and analytics
- Primary Care Physician (PCP) engagement in testing and monitoring of new treatments